Oct 22, 2026 · 13 min · 9 segments
Eyewire News the Podcast reports on new products and breaking news live from thee American Academy of Ophthalmology meeting in New Orleans. Learn more about your ad choices. Visit…
Briana ClarkHostEdenspring was recently approved for the treatment of patients with thyroid eye disease.
So thyroid eye disease is a rare autoimmune condition which affects about 155 out of every 100,000 people in the United States.
It causes inflammation and swelling in the tissue around the eyes and can lead to visual complications, bulging eyes, double vision, and sometimes even severe pain.
A further complication of thyroid eye disease is it does have, because of the disfiguring appearance, does actually have quite significant psychological comorbidities as well.
So N-Spring works by inhibiting IL-6 within the eye and it's delivered subcutaneously.
And after a loading dose, it's given every four weeks during the maintenance phase.
And one of the real advantages of EndSpring in particular is that it's the first and only approved therapy for use via the subcutaneous route, which means that it can also be delivered at home.
And this has a real advantage for patients because it offers much greater convenience than other biologics, which often require intravenous therapy inside a hospital or office setting.
The TED approval represents NSPRIM's second FDA-approved indication following its 2020 approval for neuromyelitis optica spectrum disorder.
Because it has already been approved, the treatment is now available for TED patients.
Edenspring was recently approved for the treatment of patients with thyroid eye disease.
So thyroid eye disease is a rare autoimmune condition which affects about 155 out of every 100,000 people in the United States.
It causes inflammation and swelling in the tissue around the eyes and can lead to visual complications, bulging eyes, double vision, and sometimes even severe pain.
A further complication of thyroid eye disease is it does have, because of the disfiguring appearance, does actually have quite significant psychological comorbidities as well.
So N-Spring works by inhibiting IL-6 within the eye and it's delivered subcutaneously.
And after a loading dose, it's given every four weeks during the maintenance phase.
And one of the real advantages of EndSpring in particular is that it's the first and only approved therapy for use via the subcutaneous route, which means that it can also be delivered at home.
And this has a real advantage for patients because it offers much greater convenience than other biologics, which often require intravenous therapy inside a hospital or office setting.
The TED approval represents NSPRIM's second FDA-approved indication following its 2020 approval for neuromyelitis optica spectrum disorder.
Because it has already been approved, the treatment is now available for TED patients.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
